whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation

See FDA's updated safety analysis concerning bisphophonates and atrial fibrillation

Patients are asking whether Fosamax (alendronate) and other bisphosphonates increase the risk of atrial fibrillation.

This first came up last year when researchers noted an increase in A fib in patients getting IV zoledronic acid (Reclast).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote